Structural basis for the action of the drug trametinib at KSR-bound MEK

The MAPK/ERK Kinase MEK is a shared effector of the frequent cancer drivers KRAS and BRAF that has long been pursued as a drug target in oncology(1), and more recently in immunotherapy(2,3) and aging(4). However, many MEK inhibitors (MEKi) are limited due to on-target toxicities(5–7) and drug resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Zaigham M., Real, Alexander M., Marsiglia, William M., Chow, Arthur, Duffy, Mary E., Yerabolu, Jayasudhan R., Scopton, Alex P., Dar, Arvin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746607/
https://www.ncbi.nlm.nih.gov/pubmed/32927473
http://dx.doi.org/10.1038/s41586-020-2760-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746607/
https://www.ncbi.nlm.nih.gov/pubmed/32927473
http://dx.doi.org/10.1038/s41586-020-2760-4

Ejemplares similares